• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫调节剂分泌型白细胞蛋白酶抑制剂(SLPI)在结直肠癌肝转移灶及配对的原发肿瘤中的表达与较差的预后相关。

Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis.

作者信息

Nugteren Sandrine, Goos Jeroen A C M, Delis-van Diemen Pien M, Simons-Oosterhuis Ytje, Lindenbergh-Kortleve Dicky J, van Haaften Daniëlle H, Sanders Joyce, Meijer Gerrit A, Fijneman Remond J A, Samsom Janneke N

机构信息

Laboratory of Pediatrics, Division Gastroenterology and Nutrition, Erasmus University Medical Center, Rotterdam, The Netherlands.

Departments of Clinical Neuroscience, Radiopharmacy, and Oncology & Pathology, Karolinska Institute, Stockholm, Sweden.

出版信息

Oncoimmunology. 2020 Oct 13;9(1):1832761. doi: 10.1080/2162402X.2020.1832761.

DOI:10.1080/2162402X.2020.1832761
PMID:33101778
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7556627/
Abstract

Secretory leukocyte protease inhibitor (SLPI), a pleiotropic protein expressed by healthy intestinal epithelial cells, functions as an inhibitor of NF-κB and neutrophil proteases and exerts antimicrobial activity. We previously showed SLPI suppresses intestinal epithelial chemokine production in response to microbial contact. Increased SLPI expression was recently detected in various types of carcinoma. In addition, accumulating evidence indicates SLPI expression is favorable for tumor cells. In view of these findings and the abundance of SLPI in the colonic epithelium, we hypothesized SLPI promotes colorectal cancer (CRC) growth and metastasis. Here, we aimed to establish whether SLPI expression in CRC is related to clinical outcome. Using a cohort of 507 patients with CRC who underwent resection of liver metastases, we show that high SLPI protein expression in both liver metastases and primary CRC is associated with significantly shorter overall survival after resection of liver metastases. The prognostic value of SLPI in CRC patients with liver metastases implies a role for SLPI in the formation of metastasis of human CRC. Based on the immune regulatory functions of SLPI, we anticipate that expression of SLPI provides tumors with a mechanism to evade infiltration by immune cells.

摘要

分泌型白细胞蛋白酶抑制剂(SLPI)是一种由健康肠道上皮细胞表达的多效性蛋白,它作为核因子κB(NF-κB)和中性粒细胞蛋白酶的抑制剂发挥作用,并具有抗菌活性。我们之前发现,SLPI可抑制肠道上皮细胞在接触微生物时产生趋化因子。最近在各类癌症中均检测到SLPI表达增加。此外,越来越多的证据表明,SLPI表达对肿瘤细胞有利。鉴于这些发现以及结肠上皮中SLPI的丰富表达,我们推测SLPI会促进结直肠癌(CRC)的生长和转移。在此,我们旨在确定CRC中SLPI的表达是否与临床结果相关。通过对507例行肝转移灶切除的CRC患者进行队列研究,我们发现肝转移灶和原发性CRC中SLPI蛋白的高表达均与肝转移灶切除术后的总生存期显著缩短相关。SLPI在伴有肝转移的CRC患者中的预后价值表明,SLPI在人类CRC转移形成中发挥作用。基于SLPI的免疫调节功能,我们预计SLPI的表达为肿瘤提供了一种逃避免疫细胞浸润的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab9/7556627/3f4706da5b3d/KONI_A_1832761_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab9/7556627/49c06d43f424/KONI_A_1832761_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab9/7556627/bdf557404115/KONI_A_1832761_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab9/7556627/c37eed45c8e0/KONI_A_1832761_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab9/7556627/3f4706da5b3d/KONI_A_1832761_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab9/7556627/49c06d43f424/KONI_A_1832761_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab9/7556627/bdf557404115/KONI_A_1832761_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab9/7556627/c37eed45c8e0/KONI_A_1832761_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fab9/7556627/3f4706da5b3d/KONI_A_1832761_F0004_OC.jpg

相似文献

1
Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis.免疫调节剂分泌型白细胞蛋白酶抑制剂(SLPI)在结直肠癌肝转移灶及配对的原发肿瘤中的表达与较差的预后相关。
Oncoimmunology. 2020 Oct 13;9(1):1832761. doi: 10.1080/2162402X.2020.1832761.
2
High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence.SLPI 在 III 期微卫星稳定结直肠癌中高表达与降低疾病复发相关。
Sci Rep. 2022 Jul 16;12(1):12174. doi: 10.1038/s41598-022-16427-5.
3
Secretory leukocyte protease inhibitor (SLPI) in cancer pathophysiology: Mechanisms of action and clinical implications.分泌白细胞蛋白酶抑制剂(SLPI)在癌症病理生理学中的作用机制及临床意义。
Pathol Res Pract. 2023 Aug;248:154633. doi: 10.1016/j.prp.2023.154633. Epub 2023 Jun 21.
4
Hypoxia down-regulates expression of secretory leukocyte protease inhibitor in bronchial epithelial cells via TGF-β1.缺氧通过转化生长因子-β1下调支气管上皮细胞中分泌型白细胞蛋白酶抑制剂的表达。
BMC Pulm Med. 2015 Mar 7;15:19. doi: 10.1186/s12890-015-0016-0.
5
Secretory Leukocyte Protease Inhibitor (SLPI) in mucosal tissues: Protects against inflammation, but promotes cancer.黏膜组织中的分泌型白细胞蛋白酶抑制剂(SLPI):既能抗炎,也能致癌。
Cytokine Growth Factor Rev. 2021 Jun;59:22-35. doi: 10.1016/j.cytogfr.2021.01.005. Epub 2021 Feb 10.
6
Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer.通过免疫组织化学检测分泌性白细胞蛋白酶抑制剂的表达与结直肠癌的预后和转移相关。
World J Surg Oncol. 2014 Dec 2;12:369. doi: 10.1186/1477-7819-12-369.
7
Secretory leukocyte protease inhibitor inhibits expression of polymeric immunoglobulin receptor via the NF-κB signaling pathway.分泌型白细胞蛋白酶抑制剂通过核因子κB信号通路抑制多聚免疫球蛋白受体的表达。
Mol Immunol. 2015 Oct;67(2 Pt B):568-74. doi: 10.1016/j.molimm.2015.07.021. Epub 2015 Aug 1.
8
Human buccal epithelium acquires microbial hyporesponsiveness at birth, a role for secretory leukocyte protease inhibitor.人类口腔颊黏膜在出生时获得对微生物的低反应性,这一过程与分泌型白细胞蛋白酶抑制剂有关。
Gut. 2015 Jun;64(6):884-93. doi: 10.1136/gutjnl-2013-306149. Epub 2014 Jul 23.
9
Protease inhibitory activity of secretory leukocyte protease inhibitor ameliorates murine experimental colitis by protecting the intestinal epithelial barrier.分泌型白细胞蛋白酶抑制剂的蛋白酶抑制活性通过保护肠道上皮屏障改善小鼠实验性结肠炎。
Genes Cells. 2021 Oct;26(10):807-822. doi: 10.1111/gtc.12888. Epub 2021 Aug 17.
10
Endogenous secretory leukocyte protease inhibitor inhibits microbial-induced monocyte activation.内源性分泌型白细胞蛋白酶抑制剂抑制微生物诱导的单核细胞活化。
Eur J Immunol. 2023 Feb;53(2):e2249964. doi: 10.1002/eji.202249964. Epub 2022 Dec 22.

引用本文的文献

1
SLPI as a dedifferentiation biomarker in BRAFV600E-mutant papillary thyroid cancer.SLPI作为BRAFV600E突变型甲状腺乳头状癌去分化生物标志物
Endocr Connect. 2025 Aug 14;14(8). doi: 10.1530/EC-25-0349. Print 2025 Aug 1.
2
The Role of Gene-Mediated Inflammation in Osteoarthritis.基因介导的炎症在骨关节炎中的作用。
Biomolecules. 2025 Jun 20;15(7):909. doi: 10.3390/biom15070909.
3
The chemical composition of Diwu YangGan capsule and its potential inhibitory roles on hepatocellular carcinoma by microarray-based transcriptomics.

本文引用的文献

1
Colorectal cancer liver metastases - a population-based study on incidence, management and survival.结直肠癌肝转移-基于人群的发病率、治疗和生存研究。
BMC Cancer. 2018 Jan 15;18(1):78. doi: 10.1186/s12885-017-3925-x.
2
Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers.分泌型白细胞蛋白酶抑制剂(SLPI)作为抑制三阴性乳腺癌转移的潜在靶点。
Oncotarget. 2017 Nov 26;8(65):108292-108302. doi: 10.18632/oncotarget.22660. eCollection 2017 Dec 12.
3
The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment.
基于微阵列转录组学的四物养肝胶囊化学成分及其对肝细胞癌的潜在抑制作用
J Tradit Complement Med. 2023 Dec 25;14(4):381-390. doi: 10.1016/j.jtcme.2023.12.002. eCollection 2024 Jul.
4
Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trial.转移性结直肠癌中贝伐珠单抗联合 FOLFOX 耐药的预测-PERMAD 前瞻性多中心试验结果。
PLoS One. 2024 Jun 14;19(6):e0304324. doi: 10.1371/journal.pone.0304324. eCollection 2024.
5
WFDC3 inhibits tumor metastasis by promoting the ERβ-mediated transcriptional repression of TGFBR1 in colorectal cancer.WFDC3 通过促进 ERβ 介导的 TGFBR1 的转录抑制来抑制结直肠癌的转移。
Cell Death Dis. 2023 Jul 13;14(7):425. doi: 10.1038/s41419-023-05956-0.
6
Dietary iron modulates gut microbiota and induces SLPI secretion to promote colorectal tumorigenesis.膳食铁调节肠道微生物群并诱导 SLPI 分泌以促进结直肠肿瘤发生。
Gut Microbes. 2023 Jan-Dec;15(1):2221978. doi: 10.1080/19490976.2023.2221978.
7
High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence.SLPI 在 III 期微卫星稳定结直肠癌中高表达与降低疾病复发相关。
Sci Rep. 2022 Jul 16;12(1):12174. doi: 10.1038/s41598-022-16427-5.
8
AhR Activation Leads to Attenuation of Murine Autoimmune Hepatitis: Single-Cell RNA-Seq Analysis Reveals Unique Immune Cell Phenotypes and Gene Expression Changes in the Liver.芳香烃受体激活可减轻小鼠自身免疫性肝炎:单细胞 RNA-Seq 分析揭示肝脏中独特的免疫细胞表型和基因表达变化。
Front Immunol. 2022 Jun 3;13:899609. doi: 10.3389/fimmu.2022.899609. eCollection 2022.
9
Upregulated long intergenic non-protein coding RNA 1094 (LINC01094) is linked to poor prognosis and alteration of cell function in colorectal cancer.上调的长基因间非蛋白编码 RNA 1094(LINC01094)与结直肠癌的不良预后和细胞功能改变有关。
Bioengineered. 2022 Apr;13(4):8526-8537. doi: 10.1080/21655979.2022.2051839.
结直肠癌的免疫原性与肿瘤发展及治疗的关系
Int J Mol Sci. 2016 Jun 29;17(7):1030. doi: 10.3390/ijms17071030.
4
A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis.一种乳腺癌异质性模型揭示了血管生成拟态是转移的驱动因素。
Nature. 2015 Apr 16;520(7547):358-62. doi: 10.1038/nature14403. Epub 2015 Apr 8.
5
Innate immune recognition of cancer.先天性免疫识别癌症。
Annu Rev Immunol. 2015;33:445-74. doi: 10.1146/annurev-immunol-032414-112043. Epub 2015 Jan 22.
6
Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis.葡萄糖转运蛋白1(SLC2A1)和血管内皮生长因子A(VEGFA)可预测结直肠癌肝转移切除术后的生存率。
Ann Surg. 2016 Jan;263(1):138-45. doi: 10.1097/SLA.0000000000001109.
7
Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer.通过免疫组织化学检测分泌性白细胞蛋白酶抑制剂的表达与结直肠癌的预后和转移相关。
World J Surg Oncol. 2014 Dec 2;12:369. doi: 10.1186/1477-7819-12-369.
8
Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma.德国结直肠癌肝转移的治疗:基于人群的对5772例原发性结直肠腺癌的十年分析
BMC Cancer. 2014 Nov 4;14:810. doi: 10.1186/1471-2407-14-810.
9
Human buccal epithelium acquires microbial hyporesponsiveness at birth, a role for secretory leukocyte protease inhibitor.人类口腔颊黏膜在出生时获得对微生物的低反应性,这一过程与分泌型白细胞蛋白酶抑制剂有关。
Gut. 2015 Jun;64(6):884-93. doi: 10.1136/gutjnl-2013-306149. Epub 2014 Jul 23.
10
Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases.表皮生长因子受体(EGFR)和前列腺素内过氧化物合酶2(PTGS2)是接受手术切除的结直肠癌肝转移患者的预后生物标志物。
Br J Cancer. 2014 Aug 12;111(4):749-55. doi: 10.1038/bjc.2014.354. Epub 2014 Jul 1.